AbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, highlighting progress in its immunology and metabolic disease portfolios.
The pharma giant shared encouraging Phase 2 outcomes for zumilokibart in treating moderate to severe atopic dermatitis, alongside promising Phase 1 weight-loss results for its novel amylin analog candidate, ABBV-295.
Zumilokibart Shows Efficacy In Skin Condition Trial
In the Phase 2 APEX Part B study, 346 adult participants with moderate to severe atopic dermatitis received various doses of zumilokibart or placebo over 16 weeks.
Every evaluated dose achieved statistically significant improvements in skin clearance and itch reduction compared to placebo. High- and mid-dose regimens met key secondary endpoints, including EASI 90/100 skin clearance and I-NRS4 itch scores.
The mid-dose cohort demonstrated rapid skin severity reductions by Week 1 and itch relief by Week 2.
ABBV-295 Demonstrates Weight Loss Potential
Separately, AbbVie presented Phase 1 multiple ascending dose trial results for ABBV-295 at the European Association for the Study of Diabetes 2026 Annual Meeting.
The trial assessed the subcutaneous amylin analog—a drug class distinct from GLP-1 and GIP therapies—across 60 adults with a mean body mass index of 29.3 kg/m2.
Participants receiving ABBV-295 across once-weekly, biweekly, and monthly dosing schedules achieved dose-dependent body weight reductions ranging from -7.8% to -9.8% over 12 to 13 weeks, compared with a -0.3% change in the placebo group.
The drug’s mean half-life of 10.7 to 12.3 days supported extended dosing schedules. Adverse events were mostly mild, with no serious treatment-emergent events reported.
ABBV Price Action: AbbVie shares were up 0.16% to $263.71 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo: Shutterstock
Login to comment